# The melanotan research record: mechanism, trials, and pharmacology

> melanotan mechanism of action, Phase I trial outcomes, preclinical pharmacology, and the afamelanotide clinical record. 26 primary findings indexed and cited.

## How Does Melanotan Work?

melanotan II binds all five melanocortin receptor subtypes (MC1R, MC2R, MC3R, MC4R, MC5R) with varying affinity. The two pharmacologically relevant subtypes for published MT-II research are MC1R and MC4R [2][4].

MC1R is expressed on melanocytes — the pigment-producing cells in skin, hair follicles, and mucosal tissue. When alpha-MSH or MT-II binds MC1R, the receptor activates adenylyl cyclase, elevating intracellular cyclic AMP (cAMP). Elevated cAMP activates protein kinase A (PKA), which phosphorylates the transcription factor CREB. Phosphorylated CREB drives expression of MITF — the master transcription factor of the melanocyte lineage — which in turn upregulates the enzymes tyrosinase, TYRP1, and DCT required for eumelanin synthesis [4].

MC4R is expressed predominantly in the hypothalamus and limbic structures. Its activation accounts for the appetite suppression, erectogenic signaling, and autonomic side effects documented in rodent and human studies [2][8][9][10][26]. The central MC4R pathway drives the erectile responses observed in the Wessells trials [5][6][7].

## Melanotan Peptide: Structure and Mechanism

MT-I is a linear tridecapeptide (13 amino acids), closely structurally related to endogenous alpha-MSH. Its linearity preserves MC1R selectivity; beta-phase half-life 0.8–1.7 hours subcutaneous in humans, undetectable oral bioavailability [17].

MT-II is a cyclic heptapeptide (7 amino acids: Cyclo(His-Phe-Arg-Trp-Gly), MW 1024.2 Da). The cyclic structure confers a flatter receptor-selectivity profile — binding MC1R, MC3R, MC4R, and MC5R with meaningful affinity [2]. This broader binding generates multi-system pharmacology: pigmentation via MC1R, appetite suppression and pro-erectile effects via MC4R, and thermogenesis via MC3R/MC4R in brown adipose tissue [9].

## Does Melanotan Require UV Exposure?

Phase I data (Dorr et al., 1996) showed measurable pigmentation increases without UV exposure in 2 of 3 subjects after 5 daily injections of 0.01–0.03 mg/kg [3]. MT-II activates MC1R directly — bypassing the UV-induced keratinocyte POMC pathway that normally releases endogenous alpha-MSH. Subsequent controlled observations suggest that minimal UV exposure can accelerate the pigmentation response, but UV is not required for baseline pigmentation induction [3][4].

## Melanotan Research Results: Pigmentation and Beyond

- **Pigmentation (Phase I, Dorr 1996).** 3 healthy males, 5 daily injections: measurable colorimetric pigmentation increases in 2 of 3 subjects [3]. Nausea and somnolence at higher dose levels.
- **ED (Wessells 1998).** Double-blind crossover, 10 men, psychogenic ED: 8 of 10 subjects had erections; mean tip rigidity >80% lasted 38 minutes vs. 3 minutes placebo (p=0.0045) [5].
- **ED (Wessells 2000, organic, 20 men).** 17 of 20 subjects had erections; sexual desire increased after 68% of active doses vs. 19% of placebo [6].
- **ED (Wessells 2000, organic, 10 men).** Erections in 12 of 19 active injections vs. 1 of 21 placebo; duration ~45 minutes active vs. 1.9 minutes placebo [7].
- **Adiposity (Zhang 2010, Zucker rat ICV).** ~30% food intake reduction acutely; ~80% adiposity reduction [8].
- **Adiposity (Cote 2016, F344BN rat ICV).** 35–55% intra-abdominal fat reduction; 3-fold increase in brown adipose tissue thermogenic capacity [9].
- **Nerve regeneration (Ter Laak 2003, rat).** MT-II at 20 µg/kg subcutaneous enhanced recovery after sciatic crush; bell-shaped dose-response (2 µg/kg and 50 µg/kg were ineffective) [21].

## Melanotan I (Afamelanotide) and Erythropoietic Protoporphyria

Two multicenter, double-blind, placebo-controlled Phase 3 trials evaluated 16 mg subcutaneous biodegradable implants in EPP patients [15]. US study: pain-free time in sunlight — median 69.4 hours vs. 40.8 hours placebo. EU study: phototoxic reactions 77 active vs. 146 placebo. Afamelanotide received EU approval in 2014 (Scenesse) and FDA approval in 2019.

Long-term observational study of 115 EPP patients receiving 1,023 implants over up to 8 years: quality-of-life scores rose from 31% to 74%; only minor adverse events [16].

## Evidence Gap: Photoprotection in General Population

No Phase II or Phase III trials have been completed for Melanotan II in any indication. All controlled human data for MT-II comes from small Phase I trials (3–20 subjects) on pigmentation and erectile dysfunction.

## References

[1] Lan EL et al. Preformulation studies with melanotan-II. J Pharm Sci. 1994. PMID: 7983590
[2] Hadley ME, Dorr RT. Melanocortin peptide therapeutics. Peptides. 2006. PMID: 16412534
[3] Dorr RT et al. Evaluation of melanotan-II in a pilot phase-I clinical study. Life Sci. 1996. PMID: 8637402
[4] Hida T et al. Elucidation of Melanogenesis Cascade. Int J Mol Sci. 2020. PMID: 32854423
[5] Wessells H et al. Synthetic melanotropic peptide initiates erections. J Urol. 1998. PMID: 9679884
[6] Wessells H et al. Melanocortin receptor agonists, penile erection. Int J Impot Res. 2000. PMID: 11035391
[7] Wessells H et al. Effect of alpha-MSH analog on penile erection. Urology. 2000. PMID: 11018622
[8] Zhang Y et al. Intermittent MTII application evokes repeated anorexia. Peptides. 2010. PMID: 20034526
[9] Cote I et al. Activation of the central melanocortin system. Can J Physiol Pharmacol. 2017. PMID: 28051332
[10] Eliason NL et al. Melanotan-II microinjected in nucleus accumbens. Neuropeptides. 2022. PMID: 36155088
[15] Langendonk JG et al. Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med. 2015. PMID: 26132941
[16] Biolcati G et al. Long-term observational study of afamelanotide. Br J Dermatol. 2015. PMID: 25494545
[17] Ugwu SO et al. Skin pigmentation and pharmacokinetics of melanotan-I. Biopharm Drug Dispos. 1997. PMID: 9113347
[19] Hadley ME, Dorr RT. Melanocortin peptide therapeutics (PT-141). Peptides. 2006. PMID: 16412534
[20] Rossler AS et al. Melanotan II enhances proceptive sexual behaviors in female rat. Pharmacol Biochem Behav. 2006. PMID: 17113634
[21] Ter Laak MP et al. Melanotan-II promotes peripheral nerve regeneration. Eur J Pharmacol. 2003. PMID: 12591111
[24] Bonchev A. Changes in Oral Mucosa Associated with Melanotan II. Life (Basel). 2026. PMID: 41752902
[26] Paiva L et al. Effect of Melanotan-II on Brain Fos and Oxytocin Neuronal Activity. J Neuroendocrinol. 2017. PMID: 28009464

---

A drill-down index of the peer-reviewed melanotan record — Phase I trials, preclinical mechanism studies, and documented adverse events, cited to the source.